Evidence map›Paper›PMID 39565488›Full record

ArticleAnnals of surgical oncology2025

Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.

Annie Liu, Melissa Lowe, Donna Niedzwiecki, Kristen E Rhodin, Jeremy Sharib, Benjamin Wildman-Tobriner, Terence Z Wong, Charles Y Kim, Julie Thacker, Christopher Mantyh and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Annie LiuDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Melissa LoweDuke Cancer Institute-Biostatistics Shared Resource, Durham, NC, USA.
Donna NiedzwieckiDuke Cancer Institute-Biostatistics Shared Resource, Durham, NC, USA.
Kristen E RhodinDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Jeremy SharibDepartment of Surgery, University of Washington Medical Center, Seattle, WA, USA.
Benjamin Wildman-TobrinerDepartment of Radiology, Duke University Medical Center, Durham, NC, USA.
Terence Z WongDepartment of Radiology, Duke University Medical Center, Durham, NC, USA.
Charles Y KimDepartment of Radiology, Duke University Medical Center, Durham, NC, USA.
Julie ThackerDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Christopher MantyhDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
John MigalyDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Billy Y LanDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
John H StricklerDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
S David HsuDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Daniel NussbaumDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Sabino ZaniDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Hope UronisDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Peter J AllenDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Michael E LidskyDepartment of Surgery, Duke University Medical Center, Durham, NC, USA. Michael.lidsky@duke.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggesting that implementation of a new HAI program is safe and feasible. Here, we report perioperative and oncologic outcomes from an expanded series of patients with uCRLM treated with HAI.

methodsWe analyzed outcomes from consecutive patients with uCRLM who underwent HAI pump (HAIP) placement at Duke University Hospital from 2018 to 2023. Demographics, prior treatment, and perioperative and oncologic outcomes were assessed.

resultsOverall, 102 patients underwent HAIP placement for uCRLM; 62% were male and median age was 51 years. Most patients (97%) received a median of 12 (range 0-66) prior chemotherapy cycles. Postoperative HAI-specific complications occurred in 23% of patients, including biliary sclerosis in 6%, and the 90-day mortality rate was 3%. 20% converted to resection, 4% underwent transplant, and 2% achieved complete response at 6 months after floxuridine initiation. Median hepatic and extrahepatic progression-free survival (PFS) was 15.7 months and 11.6 months, respectively. Median overall survival (OS) was 38 months from the time of pump implantation (median follow-up time: 30 months).

conclusionsHAI for uCRLM is safe, feasible, and effective at a new center, with outcomes that recapitulate those previously reported by established centers. Future analysis of our institutional data, which includes mutation status, primary tumor sidedness, and extent of prior therapy could inform selection and treatment strategies for new HAI programs.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsHepatic ArteryInfusions, Intra-ArterialLiver NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateColorectal cancer liver metastasesHepatic arterial infusion

Identifiers

PMID39565488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.